Sialic Acid Binding Ig-like Lectin 1

A sialic acid binding lectin that was originally identified as an adhesion molecule for inflammatory MACROPHAGES and activated MONOCYTES. This protein is the largest known siglec subtype and contains 16 immunoglobulin C2-set domains. It plays a role in cell to cell interactions and interactions with bacteria.

Also Known As:

Networked: 110 relevant articles (0 outcomes, 7 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Izquierdo-Useros, Nuria: 11 articles (08/2022 - 01/2012)
2.	Martinez-Picado, Javier: 11 articles (08/2022 - 01/2012)
3.	Nauwynck, Hans J: 8 articles (01/2018 - 11/2008)
4.	Crocker, Paul R: 8 articles (11/2015 - 11/2002)
5.	Telenti, Amalio: 7 articles (08/2022 - 01/2012)
6.	Erkizia, Itziar: 6 articles (08/2022 - 01/2012)
7.	Pino, Maria: 6 articles (08/2022 - 01/2012)
8.	Delputte, Peter L: 6 articles (01/2017 - 11/2008)
9.	Perez-Zsolt, Daniel: 4 articles (08/2022 - 01/2019)
10.	Benet, Susana: 4 articles (01/2020 - 05/2015)

Related Diseases

1.	Infections 01/01/2023 - "Siglec-1 mediates dissemination of HIV-1 in activated tissues enhancing viral spread via infection of DC/T-cell synapses. " 08/01/2022 - "Author Correction to: SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells." 12/01/2021 - "SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells." 02/29/2020 - "Porcine reproductive and respiratory syndrome virus up-regulates sialoadhesin via IFN-STAT signaling to facilitate its infection." 10/22/2019 - "Infection of pre-DCs is further enhanced in the presence of HIV-2/SIVmac Vpx, indicating that Siglec-1 does not counteract restriction factors such as SAMHD1. "
2.	Neoplasms (Cancer) 11/01/2023 - "The highly expressed siglec-1 receptors on the surfaces of TAMs are potential targets for cancer drug delivery systems. " 12/21/2018 - "Siglec-1 to siglec-9 were all down-regulated in tumor tissues compared with those in non-tumor tissues in HCC patients (all P < 0.05). " 12/01/1999 - "In conclusion, while SER+ macrophages are greatly decreased in bone marrow from ET bearers, this is not due to a down-regulation of sialoadhesin expression, nor to an impairment of sialoadhesin-inducing factor or to the presence of sialoadhesin-binding moieties of tumor origin, but, more likely, to a decrease of fully mature macrophages." 12/01/1999 - "Tumor progression does not impair the sialoadhesin-inducing activity of ET-bearing sera, or the ability of SER- macrophages (e.g. " 12/01/1999 - "Tumor growth is often associated with marked alterations of myelopoiesis and impairment of T cell activation; yet the expression of sialoadhesin in macrophages derived from tumor bearers has not been addressed. "
3.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/01/2019 - "This analysis confirmed increased monocytic Siglec-1 expression in active systemic lupus erythematosus patients and, additionally, revealed interrelated reductions of CD4 expression by regulatory and memory CD4 T cells and HLA-DR expression by myeloid dendritic cells, pointing toward defective cross-talk at the immunological synapse that may limit immune responses in systemic lupus erythematosus. " 04/01/2008 - "Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus." 01/01/2019 - "Given that diseases associated with anti-SSA/Ro autoantibodies, such as systemic lupus erythematosus and Sjögren syndrome, are linked with an upregulation of IFN and type I IFN-stimulated genes, including sialic acid-binding Ig-like lectin 1 (Siglec-1), a receptor on monocytes/macrophages, recent attention has focused on a potential role for IFN and IFN-stimulated genes in the pathogenesis of congenital heart block (CHB). " 07/17/2015 - "It has been shown that other sialoadhesin molecules related to CD22 have immunoregulatory functions; therefore, in the present study, we addressed the role of epratuzumab on the production of key cytokines by B cells of patients with systemic lupus erythematosus (SLE) and of healthy donors (HD). " 01/01/2018 - "The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus."
4.	Acquired Immunodeficiency Syndrome (AIDS) 03/18/2003 - "Five of the upregulated mRNAs, including Tie 1 and sialoadhesin/CD169, were confirmed by semi-quantitative PCR to be elevated in additional AIDS-KS biopsies. " 01/01/2017 - "Nonetheless, analysis of the effect of Siglec-1 truncation on progression to AIDS was not conclusive due to the limited cohort size, the lack of complete clinical records, and the restriction to study only off-therapy periods. " 11/01/2016 - "However, Siglec-1 protein truncation does not have a measurable impact on HIV-1 acquisition or AIDS outcomes in vivo. " 03/18/2003 - "Antibodies to sialoadhesin/CD169 specifically labelled tumour-associated macrophages, suggesting that macrophages present in AIDS-KS lesions belong to a subset of human CD169+ macrophages." 02/28/2007 - "Sialoadhesin mRNA was significantly elevated after HIV-1, but not HHV-8 infection, and a further increase was seen in AIDS patients. "
5.	Demyelinating Diseases (Demyelinating Disease) 04/01/2006 - "Attenuated demyelination in the absence of the macrophage-restricted adhesion molecule sialoadhesin (Siglec-1) in mice heterozygously deficient in P0." 04/01/2006 - "In the present study, we investigated the possible role of the macrophage-restricted sialic acid-binding Ig-like lectin sialoadhesin (Sn, Siglec-1) in the pathogenesis of inherited demyelination in P0(+/-) mice. "

Related Drugs and Biologics

1.	Sialic Acid Binding Immunoglobulin-like Lectins
2.	N-Acetylneuraminic Acid (Sialic Acid)
3.	Cytokines
4.	Polysaccharides (Glycans)
5.	Sialic Acids
6.	epratuzumab
7.	Proteins (Proteins, Gene)
8.	Biomarkers (Surrogate Marker)
9.	Sialic Acid Binding Ig-like Lectin 1
10.	Interferon Type I

Related Therapies and Procedures

1.	Therapeutics
2.	Heterologous Transplantation (Xenotransplantation)
3.	Transplantation
4.	Immunotherapy